Subsets in Systemic Lupus Erythematosus  by Provost, Thomas T
0022-202X/ 79/ 0072-0110$02.00/0 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, 72:110-113, 1979 
Copyright © 1979 by The Williams & Wilkins Co. 
REVIEW ARTICLE 
Vol. 72, No. 3 
Printed in U.S.A. 
Subsets in Systemic Lupus Erythematosus 
THOMAS T. PROVOST, M.D. 
The Department of Dermatology of the State University of New Yorll at Buffalo, S chool of M edicine, Bu.ffalo, New YOl'h, U.S.A . 
In recent years, evidence from several laboratories has 
indicated that various subsets of systemic lupus erythe-
matosus exist. Some of these subsets have distinctive 
mucocutaneous features but more importantly they have 
different prevalence of renal disease-thus di~er~nt 
prognosis. These subsets are defined by the specifiCIty 
of the serum antibodies the SLE patient possesses. 
Cutaneous lesions are commonly seen in systemic lupus 
erythematosus (SLE). Approximately 20% of SLE patients w~l 
demonstrate prominent cutaneous features at the onset of theIr 
disease. Furthermore, 70-80% of SLE patients will, during the 
course of their disease, display cutaneous features. This data 
indicates that a dermatologist may playa significant role in the 
early diagnosis and manageme~t of SLE. . 
SLE is a very heterogenous dIsease. Some SLE patIents have 
a life-threatening process while others, although displaying 
many systemic features, have a more benign course. Th.e·major 
course of mortality during the first 5 yr of SLE is renal Involve-
ment. ' 
SLE patients make serum antibodies against a variety of 
cellular macromolecules. These include antibodies against 
DNA, nuclear protein, histones and various RNA proteins. In 
addition, SLE patients frequently produce antibodies against 
nuclear non nucleic acids and other nuclear and cytoplasmic 
macromolecules. 
During the past 10 yr, clinical investigators have determined 
that certain antibody systems found in. SLE frequently occur in 
the presence of renal disease, whereas other antibody systems 
do not. These data indicate that SLE patients can be classified 
into specific categories (subsets) based upon serum antibodies. 
This paper is designed to briefly review the clinically significant ' 
antibody systems found in SLE and to correlate these antibody 
systems with various clinical features. To do this, I will rely 
heavily upon published data and the personal published and 
unpu blished experience obtained together with Drs. Peter J. 
Maddison and Morris Reichlin in the management of a large 
lupus clinic. 
The chemical nature of the antigen, the fluorescent staining 
pattern and the methods of detection of these clinically impor-
tant antibody systems are presented in Table 1. The designation 
of these various antibody systems is an abbreviation of the 
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surname of the patient in whose serum' the antibody system 
was originally detected. The clinical features associated with 
the specific antibodies are presented in Table II. 
I . Anti-Native DNA (nDNA) Antibodies {l,2J 
Ample evidence now exists indicating that the presence of 
anti-nDNA antibodies almost always indicates a severe prog-
nosis. These patients have a high incidence of clinical re~al 
disease and hypocomplementemia. Elution studies from kId-
neys of patients dying with SLE have ?em~nstrated an en-
hanced concentration of anti-DNA antIbodIes suggestmg a 
cause and effect relationship between the presence of DNA, 
anti-DNA immune complexes and the renal, pathology. At 
times anti-nDNA antibodies and hypocomplementemia may 
anted'ate the appearance of clinical renal disease but kidney 
biopsies of such patients will almost always detect a signific~nt 
immunological insult. The lupus band test (LBT), employmg 
noninvolved upper forearm skin, is positive 80-90% of the time 
in patients possessing anti-DNA antibodies [3,4)' More impor-
tant the LBT is usually composed of IgG alone or IgG together 
with other immunoglobulin classes [4]. Following successful 
therapy with immunosuppressive agents and/or oral steroids, 
the anti-nDNA antibodies disappear, the LBT becomes nega-
tive and serum complement levels return to normal. Reexacer-
bation of the lupus process is frequently accompanied by a 
reappearance of the anti-nDNA, hypocomplementemia and a 
positive LBT. 
Anti-nDNA antibodies are most commonly measured by 1 of 
3 techniques. These are: counterimmunoelectrophoresis, ra-
dioimmunoassay and most recently an immunofluorescent tech-
nique employing Crithidia luciliae as a substrate [5]: 
The techniques of counterimmunoelectrophoresls and ra-
dioimmunoassay can be found in any standard immunologic 
textbook. Crithidia luciliae is a nonpathogenic hemoflagellate 
containing a large mitochondrium composed of circular DNA 
(nDNA). Test sera of various dilutions are layered over the 
organisms, incubated, washed and .then ~tained with ~ ~uores­
cein conjugated anti human globulm antIserum. A pOSItIve test 
is depicted in Fig L 
Recent preliminary evidence in our laboratories suggests 
complement fixing anti-single stranded (S5) DNA antibodies 
may also be pathogenetically significant in the pro~uction , of 
lupus nephritis. We have detected several SLE patIents WIth 
severe nephritis observed over a period of years who have 
repeatedly failed to demonstrate anti-nDNA antibodies (by 
Crithidia assay) but who have possessed serum complement 
fixing anti ssDNA antibodies. 
II. Antinuclear Ribonucleic Acid Protein (anti-nRNP) (Mo) 
[6,7J 
This antibody system is directed against heat labile nuclear 
RNP and has been described in patients demonstrating features 
of the mixed connective tissue syndrome, scleroderma and SLE. 
Sharp et al [6] were the first to describe under the heading of 
the mixed connective tissue syndrome, a group of patients 
possessing anti-nRNP antibodies and having clinical features of 
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TABLE l. The chemical nature of the antigen, the fluorescent 
staining pattern, and the methods of detection of important antibody 
systems 
Anti nuclear 
Chemica l antibody Anligen 
character flu orescent. Melhod of deleclion pallern (mouse 
liver subslrale) 
nONA DNA-prole in Rim or Count.erimmunoelectro-
pe riphera l phoresis; radioiml11u-
Palt.el'l1 noassay: Cri lh idia luci-
liae 
nRNP (Mol" RNA -prolein Speckled Hemagglutination 
(h igh l ilered) Ge l double d iffusion 
Sm" Nuclear Speck led HemagglutilHltion 
glyco prolein Gel dou ble diffusion 
SSB" (Ha)" Nuclear Speckled Gel double diffusion 
glycoprote in 
Ro" Cyloplasmic None Gel double d iffusio n 
glycoprot.e in 
La" CYloplasmic None Gel double d iffl"io n 
RNA prote in 
" T he designation of' these antibody syst.ems represent an abbreviation of the 
patients' name in whose serum the antibody was init.ially delect.ecl. 
II Designation represents B antigen of Sjogren's Rynrirom e. 
TABLE II . Clinical features associated with specific antibodies ill 
SLE 
Anlibody 
DNA 
nRNP 
Sm 
SSB (Ha) 
La 
Ro 
Clinical feat.ures 
Renal disease 
Incidence of renal disease mixed connective tissue 
disease, polyserosit is, myositis and Raynaud 's 
phenomena 
Renal disease 
S icca syndrome 
S icca syndrome 
Photosensitive dermatitis 
Rena l disease 
Sicca syndrome 
both SLE a nd scleroderma. Theil' 25 patients demonstrated 
many features of scleroderma (e_g ., swollen hands, Raynaud's 
phenomena, abnormal esophageal motili ty) and indeed 4 of 
t heil- patients displayed widespread sclerodermatous cha nges. 
Further, most of t heir patients responded to t reatment with 
immunosuppressive agents and/or steroids_ 
Reichlin and Mattioli [7] have demonstrated that approxi-
mately 33% of patients satisfying the American Rheumatism 
Association 's (ARA) preliminary criteria for SLE, possess anti-
nRNP antibod ies. In a comparative study between SLE pa-
tients possessing only anti-DNA antibodies a nd those possess-
ing only ant i-nRNP, these authors failed to note the sclerod-
ermatous features found by Sharp et al in theil' patient popu-
lation. Their anti-nRNP positive patient population, on the 
contrary, was similar to the DNA positive SLE group in a ll 
respects except for the increased prevalence of pleuropericardial 
serositis, myositis and Raynaud's phenomenon in the nRNP 
group. All stud ies of SLE patients demonstrating only anti-
nRNP agree, however, that anti-nRNP antibodies are found in 
an SLE a nd mixed connective t issue patient population with a 
low prevalence of renal disease [6,7]. This latter point is most 
important to emphasize for, in our observation of over 100 SLE 
patients, we have been unable to clinically distinguish the 
majori ty of these patients possessing a nti-nRNP antibodies 
from those who do not. The clinical experience of our group 
indicates t hat the patient population possessing only ant i-
nRNP is very heterogenous. This experience is summarized in 
Table III [8]. As one can see, at one extreme a re a relatively 
small group (perhaps 10-15%) of anti-nRNP positive patients 
with clinically obvious mixed connective t issue features of SLE 
and scleroderma as described by S harp et a l. At the other 
extreme are anti-nRNP positive patients with constitut ional 
but not cutaneous signs and symptoms of a connective t issue 
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disease. In t he middle, constituting t he largest population of 
nRNP positive patients are a group of lupus patients, the vast 
majority satisfying the ARA criteria for the diagnosis of SLE. 
The major point to reemphasize is that SLE patients possessing 
only anti-nRNP antibodies have a very low incidence of renal 
disease, hence they have an excellent prognosis. 
The anti-nRNP antibodies are detected by 2 methods: a 
passive hemagglutination assay using saline soluble extractable 
nuclear antigens (hence t he term extractable nuclear antigen 
[ENA], e'mp]oyed by Sharp, in context with the mixed connec-
t ive t issue) adsorbed onto sheep red blood cells [6]. These cells 
t hen are reacted with various dilutions of test serum. Hemag-
glut ination of the red blood cells indicate the presence of serum 
antibody directed against antigens absorbed onto the red blood 
cells_ 
T he second technique employs gel double diffusion and calf 
t hymic extract (CTE) as a source of nuclear antigen_ The CTE 
FIG I. Positive Crithidia luciliae assay for an t. i-nONA antibodies. 
Mitochondria co nta ining (nONA) stain with nu orescent conjugated 
anti-human globulin serum. Serum dilution I :20 from an SLE pat.ient 
with renal disease and hypocomplementemia (reduced from X 400). 
TABI.E III. Clinical diagn.oses in 43 patients demonstrat ing ollly 
an.ti-nRNP a.lltibodies [8/ 
D iagnos is 
Mixed connective t issue disease 
Progressive systemic sclerosis 
Syst.emic lupus eryt.hemat.osus 
Hheumatoid arthritis 
Drug induced SLE 
Non-Hheumatic disease 
Number of Pal ienl s 
5 ( 12%) 
1 (2%) 
34 (80%)" 
1 (2%) 
1 (2%) 
1(2%) 
" 30 (71 %) satisfy preliminary criteria of American Hheumatological 
Association fo r SLE. 
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is placed in the center well and ' reacted with the test serum. A 
precipitin line indicates the presence of serum antibodies 
against an antigen present in the CTE. The specificity of the 
reaction is determined employing reference serum known to 
contain anti-nRNP. Figure 2 is a schematic representation of 
t his technique. 
SLE patients containing anti-nRNP are freq uently hyper-
gammaglobulinemic. Surprisingly, one study indicates t hat as 
much as 20% of the gammaglobulin fraction of these pati ents 
may contain antibody directed against nRNP . This could be 
very significant since nRNP-a nti nRNP immune complexes 
would tend to form in antibody excess. These complexes would 
be insoluble and thus be readily cleared by the reticuloendo-
thelial system. Thus, t he relat ive ease Qf clearance of the nRNP-
anti nRNP immune complexes by the reticuloendothelial sys-
tem could conceivably explain the low incidence of renal disease 
in those SLE patients possessing only anti -nRNP antibodies. 
By contrast, SLE patients make relatively small amounts of 
anti nDNA antibodies. Thus, nDNA-anti nDNA immune com-
plexes tend to form in antigen excess and are soluble. These 
complexes escape clearance by the reticuloendothelial system 
and, thus, conceivably are able to take part in the immune 
complex deposition in the kidney. 
The LBT in t hose pat ients possessing only anti-nRNP is 
usually either negative or contains only IgM [4]. In vivo spec-
kled epidermal ANA's have been noted by several groups in 
biopsies of normal skin of these patients. These patients all 
contained high titer anti-nRNP. 
111. Anti-Smith (Anti-Sm) Antibodies [9,10] 
Antibodies against the acidic nonnucleic acid nuclear mac-
romolecule termed Sm are found in approximately 25% <;>f SLE 
patien ts. This antibody system appears to be highly specific for 
SLE and preliminary evidence indicates that lupus patients 
having only this antibody system are a subset of SLE patients 
prone to develop renal disease [10]. 
This antibody system is measured by passive hemagglutina-
tion techniques as described a bove. The RNP portion of the 
extractable antigen on the sheep red blood cells is destroyed by 
RNAase prior to performance of the hemagglutination assay 
for Sm. The S m system can also be detected employing gel 
double diffusion and standard reference serum. 
IV. Anti SSB [J 1] and Ha [J2] Antibodies 
These 2 antibody systems described by 2 different groups 
appear, by gel double diffusion, to be identical antibody sys' 
terns. In this paper, these an tibody systems will be referred to 
as SSB. Thus far , the preliminary reports suggest this antibody 
system reactive against a soluble nonnucleic acid labile acid 
® . 
(8)-...· ......... 0 
FIG 2. Test serum B demonstrating precipi tin line against calf 
thymic extract (CTE) and a line of identi ty with known antibody 
system in reference serum placed in well C. The test serum B demon-
strates a line of nonidentity with known antibody system present in 
reference serum A. 
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nuclear protein a ntigen, giving a speckled nuclear flu orescence, 
is found in approximately 15% of SLE and 30% of Sjogren's 
syndrome patients. Furthermore, those SLE patients possessing 
these antigens appear to have an increased prevalence of Sjo-
gren's syndrome a nd rheumatoid factor. The rheumatoid factor 
present in the serum is not related to the anti-SSB antibodies. 
V. Anti La A ntibodies [J 3] 
The La antigen is a RNA cytoplasmic protein macromolecule. 
The anti-La antibody is found in 10-15% of SLE patients and 
approximately 30% of Sjogren's patients. Those SLE patients 
possessing this antibody system tend to have a high incidence 
of the sicca (SjogTen's) syndrome. 
VI. Anti-Ro Antibodies [5,14] 
Antibodies against this cytoplasmic, acidic non nucleic acid 
glycoprotein macromolecule of approximately 100,000-i50,000 
mw appear to be very specific for SLE and Sjogren's syndrome. 
Approximately 25% of SLE patients possess this antibody in 
their serum as do 30% of Sjogren's patients. Of 72 Ro positive 
(+) patients, 58 (81%) displayed features compatible with the 
diagnosis of SLE, 7 (10%) possessed a nonlupus collagen vas-
cular disease and 6 (8%) had no evidence of a collagen vascular 
disease. These latter 6 Ro+ patients were detected in a screen-
ing of over 5,000 hospital ized patients' sera. Those SLE patients 
demonstrating the Ro antibody system appeared to have an 
increased prevalence of photosensitivity, renal disease, Sjo-
gren's syndrome and rheumatoid factor [14]. Approximately 
75% of Ro patients also possess anti La antibodies. 
A di.rect role for antigen-antibody complex formation involv-
ing anti-Ro antibodies in the pathogenesis of the renal disease 
is suggested by elution studies of several SLE patients dying of 
renal disease which demonstrated an enhanced anti-Ro anti-
body concentration in the kidneys. 
Further studies have detected a group of Ro+ lupus patients 
who fail to demonstrate antinuclear antibody by routine im-
munofluorescent techniques employing mouse liver as a nuclear 
substrate. These patients may demonstrate a positive ANA 
when huma n tissue is utilized as a nuclear substrate (e.g. human 
spleen) . These patients frequently satisfy the ARA criteria for 
th e diagnosis of SLE. A subset of these "ANA negative" patients 
display a prominent photosensitive dermatitis which, in om' 
experience, has demanded antimalarials and/or oral cortico-
steroids to control. Our preliminary findings suggest that a large 
segment, perhaps as many as 50% of "ANA negative" lupus 
patients displaying an intense photosensitive widespread der-
matitis possess this antibody system [15]. There is no direct 
relationship between these antibodies and the widespread der-
matitis since 50% of patients with a similar if not identical 
widespread photosensitive dermatitis fail to demonstrate anti 
Ro. The point to be stressed is that these "ANA negative" 
patients possess a precipitin antibody system commonly found 
in SLE patients. 
The LBT in Ro+ patients is generally negative and if posit ive 
usually demonstrates only IgM deposition [4]. 
The anti-Ro antibodies are demonstrated by gel double dif-
fusion utilizing human spleen or liver saline extracts as a SOUl"ce 
of antigen. 
It must be emphasized that many SLE patients form anti-
bodies against several of these antigens. Thus, anti-nDNA 
a ntibodies may be seen with anti-Sm antibodies but infre-
quently with anti-nRNP. Likewise, anti-SM and anti-RNP 
appear frequently in the same patient. In these circumstances 
t he prognosis appears to be determined by the antibody asso-
ciated with the worse prognosis. Thus, SLE patients possessing 
anti-Sm and anti-RNP antibodies appear to have an incidence 
of renal disease similar to those patients possessing anti-8m 
alone. In a similar fashion the presence of anti-DNA antibodies 
irrespective of the types of additional serum antibodies appears 
almost always to carry a potentially serious prognosis. 
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This brief discussion has attempted to summarize the state 
of the "art" of serological investigations of SLE patients a nd 
t heir correla t ion with clinical features. These tests performed 
upon newly recognized SLE patients have given us the ability 
to detect those S LE patients a t risk to develop renal disease . 
Thus these tests offer the practicing physician a valuable prog-
nostic indicator in t he evaluation of SLE patients. 
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Announcement 
The 40th Annual Meeting of the Society of Investigative Dermatology will be held on May 7-9, 1979 at 
the Sheraton-Park Hotel, Washington , DC. 
Announcement 
National Psoriasis Foundation 
Summer Scholarships for Medical Students 
Predoctoral summer fellowships will be ava ila ble for support of psoriasis-related reseal'ch. Maximum 
stipend is $1,000. Deadline for applications is April 15, 1979. Applications may be obtained from : Sheldon 
R. Pinnell, M.D. , Professor of Medicine, Box 3135 Hospital, Duke University M edical Center, Durham, 
North Carolina 27710. 
